In the first week of the Year of the Horse, 857 companies disclosed their performance reports, and 4 companies saw their net profits increase by more than 10 times.

In the first week of the Year of the Horse, the performance of A-share listed companies has seen intensive disclosure. According to statistics from same Flower, as of February 28, the first week of the Year of the Horse has seen 857 A-share listed companies disclose their 2025 performance reports, with 470 companies achieving year-on-year growth in net profit attributable to the parent company. Among them, the electronics, machinery equipment, and pharmaceutical biotechnology industries ranked top three in terms of proportion, with 97, 77, and 69 companies respectively, showing strong support from their performance fundamentals. In terms of revenue growth, pharmaceutical company Haichuang Pharmaceuticals listed on the Sci-Tech Innovation board emerged as a dark horse. The performance report shows that in 2025, Haichuang Pharmaceuticals achieved operating income of 21 million yuan, a staggering 5536.26% increase year-on-year. The growth is mainly attributed to the sales of their first class 1 drug, Deng'an Zaluan Capsules, which was approved for market sales in May 2025. However, the company's net profit attributable to the parent company still showed a loss of 137 million yuan in 2025, although the loss decreased by 31.48% compared to the same period last year. Haichuang Pharmaceuticals admits that although the product has been launched, it was only included in the national medical insurance catalog in December 2025, affecting current revenue recognition due to factors such as price supplements and adjustments in marketing strategies. The company is still in the early stages of commercialization with significant investment in research and development and market, and has not yet achieved profitability.